Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to compare the analgesic efficacy and quality-of-life improvement between FSN and flunarizine hydrochloride in patients with migraine without aura. The core research questions addressed were: Q1: Whether FSN demonstrates superior or at least equivalent therapeutic effects compared to the active control drug (flunarizine hydrochloride) in pain relief and quality-of-life enhancement for migraine without aura patients; Q2: To elucidate the mechanism of FSN in treating migraine without aura from a cerebral hemodynamic perspective. Participants will:1. Group allocation: A randomized design was employed, with 30 participants enrolled per group. 2. Interventions: Experimental group: Subjected to FSN monotherapy; Control group: Treated with oral flunarizine hydrochloride. 3. Treatment duration: All participants received a 4-week therapeutic intervention. 4. Outcome measures: The following parameters were systematically evaluated during treatment and follow-up: Visual Analog Scale (VAS) scores 、Migraine-Specific Quality of Life (MSQOL) scores、Near-infrared spectroscopy (NIRS) examinations.Researchers will compare FSN to flunarizine hydrochloride(a clinically established medication) to see if FSN exhibits superior or non-inferior efficacy to treat migraine without aura.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group: Subjected to FSN monotherapy | Experimental | Participants in the FSN group received FSN treatment twice weekly for four weeks. |
|
| Control group: Treated with oral flunarizine hydrochloride | Active Comparator | Participants in the drug group were administered 5 mg flunarizine hydrochloride capsules nightly before sleep for 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fu's Subcutaneous Needling | Device | Participants were seated while the practitioner identified affected muscles (sternocleidomastoid, scalene, splenius capitis, and upper trapezius) via sliding palpation. After routine disinfection, a disposable FSN needle (Nanjing Paifu Medical Technology Co., Ltd., Jiangsu, China) was inserted parallel to the subcutaneous loose connective tissue surrounding the affected muscle. Once fully inserted, the soft tube stand was secured in the slot. After confirming no pain, the practitioner performed smooth, gentle, fan-shaped swaying movements (120° angle, ~100 times/min) with the index and ring fingers. This was accompanied by reperfusion activities-resistance-based contraction and relaxation of the affected muscles, performed collaboratively by the practitioner and participant. Each set comprised 20 swaying movements and 10 seconds of reperfusion, repeated three times per muscle. |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale (VAS) | Scored from 0 to 10, with higher scores indicating more severe pain. | baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Migraine-Specific Quality of Life (MSQOL) | including three dimensions: functional limitations, dysfunction, and emotional impact, assessed via 14 items on a 6-point scale (0-5). Scores were calculated for each dimension. | baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) |
| Headache diaries |
| Measure | Description | Time Frame |
|---|---|---|
| Near-Infrared Spectroscopy (NIRS) Imaging | Participants sat upright with the PortaLite secured over the affected PFC, positioned according to the Fp1/Fp2 landmarks of the international 10-20 EEG system . Sampling frequency was set at 50 Hz, and optodes were shielded with black cloth to minimize ambient light interference. After a 5-minute eyes-closed resting adaptation period to stabilize physiological baselines, a 2-minute resting-state recording was obtained. Following Fu's subcutaneous needling insertion into the upper trapezius (three needle sets with retention), a 5-minute post-treatment resting-state recording was acquired. Additional Fu's subcutaneous needling was administered to other target muscles post-measurement. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wenqi Guo, M.M. | Contact | 13787352592 | 13787352592@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jian Sun, M.D. | Guangzhou University of Chinese Medicine - Department of Acupuncture and Rehabilitation Clinical Medicine | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020326 | Migraine without Aura |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005444 | Flunarizine |
| ID | Term |
|---|---|
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Flunarizine Hydrochloride | Drug | Participants in the drug group were administered 5 mg flunarizine hydrochloride capsules nightly before sleep for 4 weeks. |
|
recording daily migraine episodes, including presence/absence of headache, frequency, average duration, and use of acute analgesics (if taken, drug name, dosage, and frequency were documented). |
| baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) |
| The 1st, 8th, 15th and 22nd day after the start of the treatment. |
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |